Abstract
The recent arrival of the target-specific oral anticoagulants (TSOACs) offers potential advantages in the field of anticoagulation. However, there are no rapid and accurate and routinely available laboratory assays to evaluate their contribution to clinical bleeding. With the expanding clinical indications for the TSOACs, and the arrival of newer reversal agents on the market, the emergency clinician will need to be familiar with drug specifics as well as methods for anticoagulation reversal. This review offers a summary of the literature and some practical strategies for the approach to the patient taking TSOACs and the management of bleeding in these cases.
Copyright © 2014 Elsevier Inc. All rights reserved.
MeSH terms
-
Administration, Oral
-
Anticoagulants / administration & dosage
-
Anticoagulants / adverse effects*
-
Anticoagulants / pharmacology
-
Antithrombins / administration & dosage
-
Antithrombins / adverse effects*
-
Antithrombins / pharmacology
-
Benzimidazoles / administration & dosage
-
Benzimidazoles / adverse effects
-
Benzimidazoles / pharmacology
-
Dabigatran
-
Emergency Treatment*
-
Hemorrhage / chemically induced*
-
Hemorrhage / therapy*
-
Humans
-
Morpholines / administration & dosage
-
Morpholines / adverse effects
-
Morpholines / pharmacology
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / pharmacology
-
Pyridones / administration & dosage
-
Pyridones / adverse effects
-
Pyridones / pharmacology
-
Rivaroxaban
-
Thiophenes / administration & dosage
-
Thiophenes / adverse effects
-
Thiophenes / pharmacology
-
beta-Alanine / administration & dosage
-
beta-Alanine / adverse effects
-
beta-Alanine / analogs & derivatives
-
beta-Alanine / pharmacology
Substances
-
Anticoagulants
-
Antithrombins
-
Benzimidazoles
-
Morpholines
-
Pyrazoles
-
Pyridones
-
Thiophenes
-
beta-Alanine
-
apixaban
-
Rivaroxaban
-
Dabigatran